Heat Biologics (Nasdaq:HTBX), a clinical-stage cancer immunotherapy company, said that it has completed enrollment of the full 75 patients in the blinded, randomized, placebo-controlled arms of the Phase 2 clinical trial of its drug for the treatment of high-risk, non-muscle invasive bladder cancer. Heat shares saw its shares gain a moderate rise on the news.
The Phase 2 clinical trial of HS-410 (vesigenurtacel-L) for the treatment of high-risk, non-muscle invasive bladder cancer is testing the ability of the drug to stimulate the immune system and eliminate remaining cancer cells to prevent recurrence. The primary endpoint for the Phase 2 trial is one-year disease free survival.
HS-410 is an investigational product candidate for non-invasive bladder cancer based on Heat’s proprietary ImPACT™ immunotherapy platform that is designed to generate killer T cells to attack cancers. i In March 2015, Heat received U.S. FDA Fast Track Designation for HS-410 for the treatment of NMIBC, which is designed to facilitate the development and expedite the review of potential therapies.
Heat shares sold at $4.24 in midday trading Friday, up 2 percent.